Standard versus Modified FOLFIRINOX Protocols in Patients with Metastatic Pancreatic Carcinoma: Efficacy versus Toxicity | ||
| SECI Oncology Journal | ||
| Volume 12, Issue 2, April 2024, Pages 122-125 | ||
| Abstract | ||
| Background: FOLFIRINOX revolutionized the management of patients with metastatic pancreatic adenocarcinoma (MPA). However, studies have shown severe toxicity profile leading to its limitation as a standard of care protocol. Aim: Comparison between standard and modified FOLFIRINOX in terms of response rate (RR) and toxicity profile among patients with MPA. Methods: We reviewed the medical records of 34 patients diagnosed with MPA, they were divided into two groups: standard FOLFIRINOX or modified FOLFIRINOX in the first line setting. Results: We observed no statistically significant differences in terms of response rate between the two treatment arms 30% in the standard arm and 28.6 % in the modified arm respectively. the toxicity profile was slightly better in the modified arm, namely, dose reductions14.2% vs 40 % favoring modified arm, treatment delay 28.5 % vs 50 % in the standard arm and toxicity mandating hospitalization 21.4 % vs 30 % also favoring modified arm, however this didn’t reach statistically significant difference. Conclusion: Modified FOLFIRINOX presents comparable activity compared to standard FOLFIRINOX in MPA in terms of response rate and toxicity profile favoring the modified protocol. | ||
| Keywords | ||
| FOLFIRINOX; metastatic; pancreas adenocarcinoma | ||
|
Supplementary Files
|
||
|
Statistics Article View: 65 |
||
